HYD1 peptides as anti-cancer agents

US7632814B2 · kind B2 · utility

Assignees

• University of South Florida · US
• H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US
• THE ARIZONA BOARD OF REGENTS · US
• The Regents of the University of California · US

Inventors

• Lori Hazlehurst · Morgantown, US
• William S. Dalton · Tampa, US
• Anne Cress · Tucson, US
• Kit S. Lam · Davis, US

Key dates

• Filing date: Sep 7, 2007
• Grant date: Dec 15, 2009
• Expiry date: Jan 28, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K7/06
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as myeloma. The present invention further includes a method of increasing the efficacy of chemotherapy and radiation therapy, comprising administering an agent that binds β1 integrin to a patient in need thereof. In one embodiment, the β1 integrin binding agent is the HYD1 peptide, or a functional fragment or variant thereof. In another aspect, the invention pertains to a composition (an adhesion trap) comprising a substrate (also referred to as a surface or support) with a HYD1 peptide, or fragment or variant thereof, immobilized to the substrate, and a method of removing circulating tumor cells (CTC) from blood by contacting a subject's blood with the immobilized peptide. Another aspect of the invention…